DNL (MCap £31 M) 2 Big Drugs close to EMA & FDA approval = MEGA Opp

Biomonster

Junior member
Messages
21
Likes
0
Diurnal Group has a very low valuation of only £31 Million and attractive drugs in late stage development .This undiscovered stock has significant upside potential , the fair value should be north 100p right now and more on approval of Alkindi in USA and Chronocort in Europe both expected next year .Diurnal is definitely one if not the cheapest pharma stock in UK . Lots of news expected during second half 2019 .GL

Alkindi for the treatment of paediatric adrenal insufficiency is approved in Europe (launched in UK & Germany other EU countries will follow shortly) , US-NDA submission expected in Q4 .

Chronocort for the treament of congenital adrenal hyperplasia (CAH) MAA submission to EMA for European approval in Q4 and Start of US-Phase 3 also expected in 2H 2019

Management already in discussion to partner the Drugs in USA and RoW .



Diurnal Group (DNL)

Market Cap: £31Million
Cash: £11 Million
Price: 36p

Shares Out: 84.6 million


interim-results-presentation
https://www.diurnal.co.uk/media/36769/interim-results-presentation-march-2019-pp.pdf


https://www.diurnal.co.uk/non-healt...ing-open-offer-and-notice-of-general-meeting/

Filing a Market Authorisation Application (MAA) for Chronocort® in Europe by end 2019;

Filing a New Drug Application (NDA) for Alkindi® in the US by end 2019;

Continuing the development of the European commercial organisation and roll-out of Alkindi® in Europe to maximise revenues; and

Progressing licensing discussions for Alkindi® and Chronocort® in the US and the rest of the world



Clarity for Chronocort regulatory pathwayDiurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term ‘Adrenal Franchise’. The first product, Alkindi®, is being launched in key EU markets, and this was expected to be followed by the adult version, Chronocort®. After unexpected Phase III results, positive feedback from the EMA has cleared the path for regulatory submission of Chronocort for adult CAH in Europe before the end of 2019, and allowed DNL to revise the primary endpoint in theprotocol for the US Phase III trial.


Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL’s first two products alone equates to £248m. Riskadjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share.

Diurnal also expects additional progress for Alkindi®, with further country launches scheduled during 2019 to accelerate growth of revenues,along with a planned NDA submission in the US during Q4 2019.Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI. The US remains an important market for Diurnal’s late-stage pipeline focused on cortisol deficiency, with a combined market size for the treatment of CAH and paediatric AI estimated at $132m, and a future expansion opportunity in adult AI, which represents a $0.9bn market opportunity in the US.”


Largest Shareholder:

IP Group Plc /Venture Capital/....34,410,147
Finance Wales Investments Ltd.....11,534,888
Polar Capital LLP....6,622,631
Oceanwood Capital Management LLP....3,115,166
Richard Griffiths and controlled undertakings....4,999,615
Richard John Martin Ross, MD....1,554,925
Rowan Dartington & Co. Ltd. (Broker)....1,245,000
Rathbone Investment Management Ltd.....354,000
Hargreaves Lansdown Stockbrokers Ltd.....216,000
Octopus Investments Ltd.....181,818



ImageGen.ashx


ImageGen.ashx
 
this low float stock could jump to 50p very quickly especially on good news like partner deal(s) for the US market and market launch of Alkindi in additional EU countries even buyout is possible at this very low valuation .GLTA

Live Presentation July 9, 2019 (

ObjectChart.aspx
 
going higher again but with big news like partnership ,which means upfront payments which could be higher than the entire DNL valuation of 32 Million , then this stock will be unstoppable .I think 100p+ before year end is likely .GLTA

Diurnal also expects additional progress for Alkindi®, with further country launches scheduled during 2019 to accelerate growth of revenues,along with a planned NDA submission in the US during Q4 2019.Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI. The US remains an important market for Diurnal’s late-stage pipeline focused on cortisol deficiency, with a combined market size for the treatment of CAH and paediatric AI estimated at $132m, and a future expansion opportunity in adult AI, which represents a $0.9bn market opportunity in the US.”
 
DNL is well financed after cap raising a few weeks ago and more cash will come through new Partnerships for the large markets like USA which expected anytime now . Market cap of 32 million is still a pure gift for this company . DNL can go easily above 100p and it would be still cheap .GLTA

Upcoming Milestones

Alkindi launch in additional EU States during 2H 2019

US-NDA submission for Alkindi in Q4 2019

EMA submission for Chronocort approval in Q4 2019

US-Partner Deal for Alkindi could happen anytime now

US-Partner Deal for Chronocort could happen anytime now

Partner Deal(s) for Alkindi and Chronocort for RoW could happen anytime now
 
and uuuuup she goes again ,,, but this undiscovered stock is still a pure gift at market cap of 34 million

p.php
 
Big US-Partnership news which means upfront payments to DNL could hit the wire anytime now such news could push this low float stock 50-100% because of its very low valuation (£35.5 Million) .GL

"Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI. "


chart.aspx
 
up she goes again now trading at 46.2p or 8.7%+ , and DNL is still heavily underpriced at 39 million valuation .The Big News still to come which could push this undiscovered stock even faster to the upside .


Upcoming Milestones

Alkindi launch in additional EU States during 2H 2019

US-NDA submission for Alkindi in Q4 2019

EMA submission for Chronocort approval in Q4 2019

US-Partner Deal for Alkindi could happen anytime now

US-Partner Deal for Chronocort could happen anytime now

Partner Deal(s) for Alkindi and Chronocort for RoW could happen anytime now
 
Shareholders here should put a high gtc sell order in like 100p ,so your shares will not available for shorts and more important it reduces the free shares on market so it helps the stock to make even much bigger jumps on good news . Thank you guys

How to Prevent your Shares Holdings from being Shorted
https://www.contracts-for-difference.com/Borrowing-lending-shares.html

Q:What can you do to prevent your shares holdings from being shorted?

A: Now what can the average personal investor do to stop their own shares being shorted, as believe me your own broker, if approached, WILL sell your own shares that they hold on your behalf as a nominee account.

There are two things you can do, the first is to certificate them but this is not obviously to everyone’s advantage but the alternative solution is simple. All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today’s price. As they are ‘on order’ they cannot be lent out by your broker and in turn you are reducing the amount of ‘free shares’ out there that can be used for shorting purposes. And don’t forget to move your limit order up when the price starts to recover, then, that way your shares can’t be shorted – not much but helps :D.

Although an individual personal investor will not normally have enough shares to halt a concerted shorting attack, if a large number of holders did this it would reduce the overall amount of shares that they could get their hands on.

In my opinion well worth doing if not only for the knowledge that your own shares cannot and will not be used in a short attack against the very share that you own.
 
love this undiscovered stock its almost everyday in the green ..Market cap still at laughable 40 million makes this one the most attractive and underpriced UK pharma stock and it could hit 100p+ in no time on those news below upfront payments from potential US-Partnership alone could be higher than the entire valuation of DNL .STRONG BUY


Upcoming Milestones


Alkindi launch in additional EU States during 2H 2019


US-NDA submission for Alkindi in Q4 2019


EMA submission for Chronocort approval in Q4 2019


US-Partner Deal for Alkindi could happen anytime now


US-Partner Deal for Chronocort could happen anytime now


Partner Deal(s) for Alkindi and Chronocort for RoW could happen anytime now


"Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI."



ObjectChart.aspx
 
the selloff on the stock markets created a great buying opportunity on this still undiscovered goldmine .GL
--------

Send an email to the company askting if they are still on track for NDA and MAA submission of their drugs and about potential partnerships . Below is the response

Dear Mr XXXXXXXX,

I can answer your questions as far as the information is already in the public domain.

I can confirm the Alkindi NDA submission and Chronocort MAA submission remain on track for Q4 2019.

We have disclosed to the market that we are in US licensing discussions. We have not put a timeline on a deal, other than to comment that we would like to have a commercial partner in place for Alkindi around the time of the NDA submission – so it is possible we could see partnerships before the end of 2019.

We share your frustrations regarding the share price but do expect it to remain volatile until we get closer to potential approvals in the US and Europe.

As I mentioned before, we have a very active investor relations programme, and do announce all significant newsflow as it happens.

Best regards
Richard Bungay
 
back up she goes looks like consolidation is over , with goods news this underpriced low float stock will hit 100p quickly and many big milestones expected during 2H 2019 .GL
 
the good news is there are no sellers here but looks like we have to wait until news hit the wire .DNL still the most attractive and underpriced pharma stock in UK , searching the entire uk healthcare sector and doesnt find a better one than DNL .
 
Great news out today and much more to come ...

Diurnal (DNL) Price: 30 p --Market Cap £26 M --Cash £9 M--MEGA milestones expected within 4 weeks = 300-500% GEM

Approaching anumber of near-term milestones....5 November 2019

Valuation -DCF 202p per share

The consequence of the Chronocort trial outcome is minimal in the bigger picture, as it has delayed both the EMA MAA submission and the start of the US Phase III trial only by about six months. Hence, there has not been a material change to our DCF valuation based on our clearly-stated assumptions in ourresearch note, published on 25 April 2019. The net present value of the cashflows that could be generated from DNL’s first two products equates to £305m. Risk-adjustment to take account of the different stages of development in different territories reduces this to £171m, or 202p per share.





DITEST™(Hypogonadism) study readout Q4 2019

Alkindi® US NDA submission to the FDA(paediatric AI,including CAH) Q4 2019

Chronocort® European regulatory submission to the EMA(CAH) Q4 2019

Conclude US partnering discussions for Alkindi®(Chronocort®) H1 2020



Presentation
 
The most underpriced and attractive british biotech company with MASSIVE upside potential .Still think this sleeping giant has 10+ bagger upside potential and 2020 could be the year for DNL with all the approvals and partnerships expected during the year .GL



Diurnal (DNL)
Market Cap £24 M
Price: 29p


DCF valuation of 202p per share

Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses

Presentation


Upcoming Catalysts:

US-NDA acceptance for Alkindi in Februry 2020

MAA-Acceptance for Chronocort in February/March 2020

Alkindi approval in Israel expected in 1Q 2020

Alkindi approval in Australien expected in 2Q 2020

US-Partnership for Alkindi & Chronocort expected in 1H 2020

Alkindi & Chronocort Partnership for Asia für Japan und China

US-Approval for Alkindi expected in 4Q 2020

EU Approval for Chronocort expected in 4Q/1Q 2020/21


$88m market opportunity (Europe and US) for Paediatric AI (inc CAH)
$351m market opportunity (Europe and US) for Congenital Adrenal Hyperplasia
$2,767m market opportunity (Europe and US) for Adrenal Insufficiency



Ceo bought another 25k shares at 30p
 
GREAT News out today ..NDA accepted by FDA and the Drug could be approved in Q3 .. Still the CHEAPEST and most attractive small cap Biotech in UK . A potential 10 Bagger here


Diurnal : US FDA Accepts NDA Application for Alkindi

Application seeks approval of Alkindi® Sprinkle as a replacement therapy of adrenal insufficiency in infants, children and adolescents

NDA could potentially be approved in Q3 2020



Diurnal (DNL)
Market Cap £23 M
Price: 28p


New Presentation
 
DNL =BIG Drug with potential FDA approval in 2 months = 5+ BAGGER GEM

Diurnal Group (DNL) = MCap £38 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping iant here .GL

Market Cap £38 million
Cash £15 million
Price 30p


Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29
EMA Decision for Chronocort expected in early Q1 2021
 
Top